The number of patients with any hormone receptor (HR)/HER2 positive clinical subtype was 180 (36.2%), the number with triple-negative breast cancer (TNBC) was 175 (35.1%), and the number with an HR positive /HER2 negative clinical subtype was 143 (28.7%). The gene discussed is NR4A1; the disease is triple-negative breast carcinoma.